Radical Cystectomy Compared to Combined Modality Treatment for Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
To perform a comprehensive comparison of overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), and treatment-related complications between radical cystectomy (RC) and combined modality treatment (CMT—radiation therapy, concurrent chemotherapy, and maximal transuret...
Saved in:
Published in | International journal of radiation oncology, biology, physics Vol. 97; no. 5; pp. 1002 - 1020 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.04.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | To perform a comprehensive comparison of overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), and treatment-related complications between radical cystectomy (RC) and combined modality treatment (CMT—radiation therapy, concurrent chemotherapy, and maximal transurethral resection of bladder tumor) in the setting of muscle-invasive bladder cancer.
We searched 7 databases (PubMed, Scopus, EMBASE, Proquest, CINAHL, and ClinicalTrials.gov) for randomized, controlled trials and prospective and retrospective studies directly comparing RC with CMT from database inception to March 2016. We conducted meta-analyses evaluating OS, DSS, and PFS with hazard ratios (HRs) and 95% confidence intervals (CIs).
Nineteen studies evaluating 12,380 subjects were selected. For the 8 studies encompassing 9554 subjects eligible for meta-analyses, we found no difference in OS at 5 years (HR 0.96, favoring CMT, 95% CI 0.72-1.29; P=.778) or 10 years (HR 1.02, favoring cystectomy, 95% CI 0.73-1.42; P=.905). No difference was observed in DSS at 5 years (HR 0.83, favoring radiation, 95% CI 0.54-1.28; P=.390) or 10 years (HR 1.17, favoring cystectomy, 95% CI 0.89-1.55; P=.264), or PFS at 10 years (HR 0.85, favoring CMT, 95% CI 0.43-1.67; P=.639). The cystectomy arms had higher rates of early major complications, whereas rates of minor complications were similar between the 2 treatments.
Current meta-analysis reveals no differences in OS, DSS, or PFS between RC and CMT. Further randomized, controlled trials are necessary to identify the optimal treatment for specific patients. |
---|---|
AbstractList | To perform a comprehensive comparison of overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), and treatment-related complications between radical cystectomy (RC) and combined modality treatment (CMT—radiation therapy, concurrent chemotherapy, and maximal transurethral resection of bladder tumor) in the setting of muscle-invasive bladder cancer.
We searched 7 databases (PubMed, Scopus, EMBASE, Proquest, CINAHL, and ClinicalTrials.gov) for randomized, controlled trials and prospective and retrospective studies directly comparing RC with CMT from database inception to March 2016. We conducted meta-analyses evaluating OS, DSS, and PFS with hazard ratios (HRs) and 95% confidence intervals (CIs).
Nineteen studies evaluating 12,380 subjects were selected. For the 8 studies encompassing 9554 subjects eligible for meta-analyses, we found no difference in OS at 5 years (HR 0.96, favoring CMT, 95% CI 0.72-1.29; P=.778) or 10 years (HR 1.02, favoring cystectomy, 95% CI 0.73-1.42; P=.905). No difference was observed in DSS at 5 years (HR 0.83, favoring radiation, 95% CI 0.54-1.28; P=.390) or 10 years (HR 1.17, favoring cystectomy, 95% CI 0.89-1.55; P=.264), or PFS at 10 years (HR 0.85, favoring CMT, 95% CI 0.43-1.67; P=.639). The cystectomy arms had higher rates of early major complications, whereas rates of minor complications were similar between the 2 treatments.
Current meta-analysis reveals no differences in OS, DSS, or PFS between RC and CMT. Further randomized, controlled trials are necessary to identify the optimal treatment for specific patients. Purpose To perform a comprehensive comparison of overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), and treatment-related complications between radical cystectomy (RC) and combined modality treatment (CMT—radiation therapy, concurrent chemotherapy, and maximal transurethral resection of bladder tumor) in the setting of muscle-invasive bladder cancer. Methods and Materials We searched 7 databases (PubMed, Scopus, EMBASE, Proquest, CINAHL, and ClinicalTrials.gov ) for randomized, controlled trials and prospective and retrospective studies directly comparing RC with CMT from database inception to March 2016. We conducted meta-analyses evaluating OS, DSS, and PFS with hazard ratios (HRs) and 95% confidence intervals (CIs). Results Nineteen studies evaluating 12,380 subjects were selected. For the 8 studies encompassing 9554 subjects eligible for meta-analyses, we found no difference in OS at 5 years (HR 0.96, favoring CMT, 95% CI 0.72-1.29; P =.778) or 10 years (HR 1.02, favoring cystectomy, 95% CI 0.73-1.42; P =.905). No difference was observed in DSS at 5 years (HR 0.83, favoring radiation, 95% CI 0.54-1.28; P =.390) or 10 years (HR 1.17, favoring cystectomy, 95% CI 0.89-1.55; P =.264), or PFS at 10 years (HR 0.85, favoring CMT, 95% CI 0.43-1.67; P =.639). The cystectomy arms had higher rates of early major complications, whereas rates of minor complications were similar between the 2 treatments. Conclusion Current meta-analysis reveals no differences in OS, DSS, or PFS between RC and CMT. Further randomized, controlled trials are necessary to identify the optimal treatment for specific patients. To perform a comprehensive comparison of overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), and treatment-related complications between radical cystectomy (RC) and combined modality treatment (CMT-radiation therapy, concurrent chemotherapy, and maximal transurethral resection of bladder tumor) in the setting of muscle-invasive bladder cancer.PURPOSETo perform a comprehensive comparison of overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), and treatment-related complications between radical cystectomy (RC) and combined modality treatment (CMT-radiation therapy, concurrent chemotherapy, and maximal transurethral resection of bladder tumor) in the setting of muscle-invasive bladder cancer.We searched 7 databases (PubMed, Scopus, EMBASE, Proquest, CINAHL, and ClinicalTrials.gov) for randomized, controlled trials and prospective and retrospective studies directly comparing RC with CMT from database inception to March 2016. We conducted meta-analyses evaluating OS, DSS, and PFS with hazard ratios (HRs) and 95% confidence intervals (CIs).METHODS AND MATERIALSWe searched 7 databases (PubMed, Scopus, EMBASE, Proquest, CINAHL, and ClinicalTrials.gov) for randomized, controlled trials and prospective and retrospective studies directly comparing RC with CMT from database inception to March 2016. We conducted meta-analyses evaluating OS, DSS, and PFS with hazard ratios (HRs) and 95% confidence intervals (CIs).Nineteen studies evaluating 12,380 subjects were selected. For the 8 studies encompassing 9554 subjects eligible for meta-analyses, we found no difference in OS at 5 years (HR 0.96, favoring CMT, 95% CI 0.72-1.29; P=.778) or 10 years (HR 1.02, favoring cystectomy, 95% CI 0.73-1.42; P=.905). No difference was observed in DSS at 5 years (HR 0.83, favoring radiation, 95% CI 0.54-1.28; P=.390) or 10 years (HR 1.17, favoring cystectomy, 95% CI 0.89-1.55; P=.264), or PFS at 10 years (HR 0.85, favoring CMT, 95% CI 0.43-1.67; P=.639). The cystectomy arms had higher rates of early major complications, whereas rates of minor complications were similar between the 2 treatments.RESULTSNineteen studies evaluating 12,380 subjects were selected. For the 8 studies encompassing 9554 subjects eligible for meta-analyses, we found no difference in OS at 5 years (HR 0.96, favoring CMT, 95% CI 0.72-1.29; P=.778) or 10 years (HR 1.02, favoring cystectomy, 95% CI 0.73-1.42; P=.905). No difference was observed in DSS at 5 years (HR 0.83, favoring radiation, 95% CI 0.54-1.28; P=.390) or 10 years (HR 1.17, favoring cystectomy, 95% CI 0.89-1.55; P=.264), or PFS at 10 years (HR 0.85, favoring CMT, 95% CI 0.43-1.67; P=.639). The cystectomy arms had higher rates of early major complications, whereas rates of minor complications were similar between the 2 treatments.Current meta-analysis reveals no differences in OS, DSS, or PFS between RC and CMT. Further randomized, controlled trials are necessary to identify the optimal treatment for specific patients.CONCLUSIONCurrent meta-analysis reveals no differences in OS, DSS, or PFS between RC and CMT. Further randomized, controlled trials are necessary to identify the optimal treatment for specific patients. |
Author | Vashistha, Vishal Liss, Michael A. Kaushik, Dharam Wang, Hanzhang Mazzone, Andrew Svatek, Robert S. Schleicher, Mary |
Author_xml | – sequence: 1 givenname: Vishal surname: Vashistha fullname: Vashistha, Vishal organization: Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio – sequence: 2 givenname: Hanzhang surname: Wang fullname: Wang, Hanzhang organization: Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas – sequence: 3 givenname: Andrew surname: Mazzone fullname: Mazzone, Andrew organization: Rush Medical College, Rush University Medical Center, Chicago, Illinois – sequence: 4 givenname: Michael A. surname: Liss fullname: Liss, Michael A. organization: Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas – sequence: 5 givenname: Robert S. surname: Svatek fullname: Svatek, Robert S. organization: Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas – sequence: 6 givenname: Mary surname: Schleicher fullname: Schleicher, Mary organization: Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio – sequence: 7 givenname: Dharam surname: Kaushik fullname: Kaushik, Dharam email: Kaushik@uthscsa.edu organization: Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28332983$$D View this record in MEDLINE/PubMed https://www.osti.gov/biblio/22649890$$D View this record in Osti.gov |
BookMark | eNqVUkuLFDEYDLLiPvQfiAS8eOkxj062exFhHHws7CLszsFbSCdfY8buZDbJjPTdH27aWT0IsnhKQqoqqarvFB354AGh55QsKKHy9WbhNjF02wUrpwWlCyLkI3RCm_O24kJ8OUInhEtS8XJ9jE5T2hBCKD2vn6Bj1nDO2oafoB832jqjB7yaUgaTwzjhVRi3OoLFOcz7zvmyvw5WDy5PeB1B5xF8xn2I-HqXzADVpd_r5PaA3w3aWoh4pb2BeIGX-HYWHnV2Bt_A3sF3rH2Rg6yrpdfDlFx6ih73ekjw7H49Q-sP79erT9XV54-Xq-VVZYSsc9VKoVkvLSPECAFARQu1qGlnaimanoA02jbQM67BkoZ1hPPeFgwxhHWCn6GXB9mQslPJuGL4qwneF9-KMVm3TUsK6tUBtY3hbgcpq9ElA8OgPYRdUrRpSC1b2fICfXEP3XUjWLWNbtRxUr_jLYD6ADAxpBSh_wOhRM0tqo06tKjmFhWlqrRYaBd_0cpfS4LB56jd8BD57YEMJcmSd5ydQmnDujgbtcH9r4AZnJ-H5BtMkDZhF0tvJQiVmCLqdp6yecio5FzUvxJ882-Bh9__Cd5x5Gk |
CitedBy_id | crossref_primary_10_1371_journal_pone_0216255 crossref_primary_10_5935_2526_8732_20210016 crossref_primary_10_3233_BLC_189037 crossref_primary_10_1177_17588359241249068 crossref_primary_10_36290_uro_2020_042 crossref_primary_10_1186_s13014_023_02338_w crossref_primary_10_1007_s11912_018_0711_0 crossref_primary_10_1007_s15004_019_6552_7 crossref_primary_10_1016_j_hoc_2021_02_006 crossref_primary_10_1080_02656736_2023_2275540 crossref_primary_10_1007_s00345_018_2606_y crossref_primary_10_1016_j_urolonc_2019_09_008 crossref_primary_10_1097_COC_0000000000000491 crossref_primary_10_1007_s00761_022_01213_9 crossref_primary_10_1007_s00120_024_02420_5 crossref_primary_10_1093_jrr_rrad027 crossref_primary_10_3390_medicina59010050 crossref_primary_10_1016_j_eururo_2019_01_011 crossref_primary_10_1007_s00761_017_0293_8 crossref_primary_10_1016_j_ajur_2021_10_002 crossref_primary_10_1016_j_clgc_2018_09_021 crossref_primary_10_3390_cancers15010041 crossref_primary_10_1016_j_clgc_2018_09_023 crossref_primary_10_1200_JCO_19_02035 crossref_primary_10_1007_s00066_018_1274_6 crossref_primary_10_1016_j_semradonc_2022_10_005 crossref_primary_10_1186_s13014_023_02348_8 crossref_primary_10_1016_j_clon_2022_05_017 crossref_primary_10_1259_bjr_20200241 crossref_primary_10_1007_s12094_023_03264_9 crossref_primary_10_1016_j_urolonc_2020_11_023 crossref_primary_10_1016_j_canrad_2022_06_009 crossref_primary_10_1097_MOU_0000000000000601 crossref_primary_10_1007_s00345_020_03436_0 crossref_primary_10_1038_s41572_023_00468_9 crossref_primary_10_1093_jrr_rraa039 crossref_primary_10_1080_14712598_2019_1604673 crossref_primary_10_1007_s12094_018_02001_x crossref_primary_10_1016_j_csbj_2024_10_007 crossref_primary_10_4103_jcrt_jcrt_1661_21 crossref_primary_10_1002_cam4_2126 crossref_primary_10_1016_j_clgc_2021_11_002 crossref_primary_10_1177_0300891618766109 crossref_primary_10_1016_j_urology_2018_07_058 crossref_primary_10_1007_s00066_023_02134_1 crossref_primary_10_1016_S1470_2045_18_30693_4 crossref_primary_10_1016_j_urology_2018_07_060 crossref_primary_10_1016_j_radonc_2022_01_008 crossref_primary_10_1007_s15004_018_6096_2 crossref_primary_10_1016_j_euo_2022_10_003 crossref_primary_10_1016_j_urology_2018_07_061 crossref_primary_10_1080_14737140_2020_1736565 crossref_primary_10_1007_s00120_018_0628_0 crossref_primary_10_1007_s11934_018_0859_z crossref_primary_10_1016_j_annonc_2021_11_012 crossref_primary_10_3233_BLC_200291 crossref_primary_10_1016_j_urolonc_2020_09_001 crossref_primary_10_15406_ijrrt_2024_11_00407 crossref_primary_10_1007_s00120_023_02194_2 crossref_primary_10_1016_j_canrad_2023_06_011 crossref_primary_10_1007_s12094_022_02815_w crossref_primary_10_1177_03915603241256009 crossref_primary_10_3322_caac_21631 crossref_primary_10_1007_s13566_018_0347_6 crossref_primary_10_1016_j_ijrobp_2018_12_028 crossref_primary_10_1016_j_ctro_2021_08_001 crossref_primary_10_1016_j_ctro_2021_08_003 crossref_primary_10_1016_j_critrevonc_2021_103235 crossref_primary_10_1016_j_urolonc_2020_10_004 crossref_primary_10_1016_j_urolonc_2020_10_005 crossref_primary_10_1080_0284186X_2022_2101381 crossref_primary_10_1007_s11912_020_0880_5 crossref_primary_10_1016_j_ijrobp_2017_11_040 crossref_primary_10_1097_JU9_0000000000000132 crossref_primary_10_1097_MOU_0000000000001113 crossref_primary_10_1200_EDBK_432054 crossref_primary_10_36106_ijsr_7600504 crossref_primary_10_1016_j_urology_2019_05_062 crossref_primary_10_1007_s11864_020_00800_5 crossref_primary_10_26779_2522_1396_2020_9_10_63 crossref_primary_10_1007_s00120_021_01712_4 crossref_primary_10_1016_j_clon_2021_03_021 crossref_primary_10_1007_s00120_022_01963_9 crossref_primary_10_1016_j_ijrobp_2017_07_002 crossref_primary_10_1016_j_urolonc_2021_05_036 crossref_primary_10_1016_j_ijrobp_2017_07_001 crossref_primary_10_3390_jcm12041560 crossref_primary_10_1200_EDBK_201227 |
Cites_doi | 10.1016/j.juro.2011.09.159 10.3322/caac.21254 10.1016/j.radonc.2009.04.020 10.1111/j.1464-410X.2010.09537.x 10.4103/0973-1482.34684 10.1002/sim.1303 10.1017/S1460396914000107 10.1007/s00345-013-1123-2 10.1016/j.canep.2009.08.008 10.1200/jco.2014.32.4_suppl.334 10.1136/bmj.327.7414.557 10.1016/j.eururo.2005.03.022 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8 10.1016/j.critrevonc.2015.04.006 10.1016/j.clon.2003.10.001 10.1016/j.ijrobp.2009.04.050 10.1080/21681805.1991.12068888 10.1016/j.juro.2011.02.1879 10.1016/S0302-2838(02)00581-X 10.1111/j.1464-410X.1976.tb06705.x 10.1016/j.eururo.2011.11.010 10.1016/j.juro.2015.02.2635 10.1111/j.1464-410X.1989.tb05185.x 10.1016/j.ijrobp.2012.07.211 10.1002/1097-0142(197702)39:2+<973::AID-CNCR2820390737>3.0.CO;2-O 10.1016/S1569-9056(14)60124-X 10.1016/j.eururo.2005.04.006 10.1111/j.1464-410X.2008.07636.x 10.1016/j.asjsur.2014.01.010 10.1097/COC.0b013e318199fb42 10.7326/0003-4819-151-4-200908180-00135 10.4103/0970-1591.38603 10.1016/j.ijrobp.2007.06.030 10.1186/1471-2407-8-250 10.1111/j.1464-410X.1982.tb13537.x 10.1016/j.urolonc.2014.09.014 |
ContentType | Journal Article |
Copyright | 2016 Elsevier Inc. Elsevier Inc. Copyright © 2016 Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: 2016 Elsevier Inc. – notice: Elsevier Inc. – notice: Copyright © 2016 Elsevier Inc. All rights reserved. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 OTOTI |
DOI | 10.1016/j.ijrobp.2016.11.056 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic OSTI.GOV |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1879-355X |
EndPage | 1020 |
ExternalDocumentID | 22649890 28332983 10_1016_j_ijrobp_2016_11_056 S0360301616335490 1_s2_0_S0360301616335490 |
Genre | Meta-Analysis Systematic Review Journal Article |
GroupedDBID | --- --K .1- .FO 0R~ 1B1 1P~ 1RT 1~5 4.4 457 4G. 53G 5RE 7-5 AAEDT AAEDW AAQQT AAWTL AAXUO ABJNI ABLJU ABNEU ABOCM ABUDA ACGFS ACIUM ACVFH ADBBV ADCNI ADVLN AENEX AEUPX AEVXI AFPUW AFRHN AFTJW AGCQF AHHHB AIGII AITUG AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ BELOY DU5 EBS EFKBS EJD F5P FDB GBLVA HED HMO IHE J1W KOM LX3 M41 MO0 O9- OC~ OO- RNS ROL RPZ SDG SEL SES SSZ UV1 XH2 Z5R ~S- .55 .GJ 29J 5VS AALRI AAQFI AAQXK ABEFU ABWVN ACRPL ADMUD ADNMO ADPAM AFCTW AFFNX AFJKZ AGRDE ASPBG AVWKF AZFZN EFJIC FEDTE FGOYB FIRID G-2 HMK HVGLF HX~ HZ~ NQ- R2- RIG SAE SEW UDS X7M XPP ZGI AAIAV AGZHU ALXNB ZA5 AAYWO AAYXX AGQPQ CITATION CGR CUY CVF ECM EIF NPM 7X8 ABPTK OTOTI |
ID | FETCH-LOGICAL-c564t-965a2f6d200c55ee159e4541bc4658f0e6cad8ef23aed082b033fd9e40c02b53 |
ISSN | 0360-3016 1879-355X |
IngestDate | Thu May 18 18:35:48 EDT 2023 Fri Jul 11 09:47:51 EDT 2025 Mon Jul 21 05:22:14 EDT 2025 Tue Jul 01 02:23:29 EDT 2025 Thu Apr 24 22:53:43 EDT 2025 Fri Feb 23 02:28:08 EST 2024 Tue Feb 25 20:10:00 EST 2025 Tue Aug 26 16:58:42 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Language | English |
License | Copyright © 2016 Elsevier Inc. All rights reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c564t-965a2f6d200c55ee159e4541bc4658f0e6cad8ef23aed082b033fd9e40c02b53 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 ObjectType-Undefined-4 |
PMID | 28332983 |
PQID | 1880469693 |
PQPubID | 23479 |
PageCount | 19 |
ParticipantIDs | osti_scitechconnect_22649890 proquest_miscellaneous_1880469693 pubmed_primary_28332983 crossref_primary_10_1016_j_ijrobp_2016_11_056 crossref_citationtrail_10_1016_j_ijrobp_2016_11_056 elsevier_sciencedirect_doi_10_1016_j_ijrobp_2016_11_056 elsevier_clinicalkeyesjournals_1_s2_0_S0360301616335490 elsevier_clinicalkey_doi_10_1016_j_ijrobp_2016_11_056 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2017-04-01 |
PublicationDateYYYYMMDD | 2017-04-01 |
PublicationDate_xml | – month: 04 year: 2017 text: 2017-04-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | International journal of radiation oncology, biology, physics |
PublicationTitleAlternate | Int J Radiat Oncol Biol Phys |
PublicationYear | 2017 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | Miller (bib18) 1977; 39 Sun, Gandaglia, Pierre (bib37) 2014; 32 Siegel, Miller, Jemal (bib1) 2015; 65 Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at Chamie, Hu, Devere White (bib13) 2008; 102 Accessed November 17, 2016. Sell, Jakobsen, Nerstrom (bib21) 1991; 138 Wallace, Bloom (bib25) 1976; 48 Azuma, Yamamoto, Inamoto (bib10) 2009; 32 Kalogeras, Lampri, Goussia (bib16) 2008; 13 Parmar, Torri, Stewart (bib5) 1998; 17 Higgins, Thompson, Deeks (bib7) 2003; 327 Eswara, Efstathiou, Heney (bib32) 2012; 187 Gofrit, Nof, Meirovitz (bib14) 2015; 33 Fedewa, Soliman, Ismail (bib30) 2009; 33 Zarzour, Selim, Abd-Elsayed (bib31) 2008; 8 (bib2) 2005; 48 Nieuwenhuijzen, Pos, Moonen (bib20) 2005; 48 Moher, Liberati, Tetzlaff (bib4) 2009; 151 Haresh, Julka, Sharma (bib15) 2007; 3 Munro, Sundaram, Weston (bib19) 2010; 77 Shelley, Wilt, Barber (bib28) 2004; 16 Williamson, Smith, Hutton (bib6) 2002; 21 van der Steen-Banasik, Ploeg, Witjes (bib24) 2009; 93 Arcangeli, Strigari, Arcangeli (bib29) 2015; 95 Yadav, Ghoshal, Sharma (bib26) 2008; 24 Sun, Gandaglia, Larcher (bib38) 2015; 193 Huddart, Hall, Lewis (bib34) 2010; 106 Mameghan, Fisher (bib27) 1989; 63 Supit, Mochtar, Santoso (bib22) 2014; 37 Pokala N, Agarwal P, Kiran RP, et al. Comparative survival following different treatment modalities for stage T2-muscle invasive bladder cancer in octogenarians—a population based study. Presented at the Annual Meeting of the American Urological Association, May 14-19, 2011, Washington, DC. Chahal, Sundaram, Iddenden (bib12) 2003; 43 Efstathiou, Spiegel, Shipley (bib3) 2012; 61 Kotwal, Choudhury, Johnston (bib17) 2008; 70 Sujenthiran, Van Der Meulen, Kelly (bib36) 2014; 13 AlGizawy, Essa, Abdel-Wanis (bib9) 2014; 13 Bloom, Hendry, Wallace (bib11) 1982; 54 Huddart, Birtle, Lewis (bib33) 2012; 84 Trulson, Sharma, Haden (bib23) 2014; 32 Chahal (10.1016/j.ijrobp.2016.11.056_bib12) 2003; 43 Wallace (10.1016/j.ijrobp.2016.11.056_bib25) 1976; 48 Nieuwenhuijzen (10.1016/j.ijrobp.2016.11.056_bib20) 2005; 48 Zarzour (10.1016/j.ijrobp.2016.11.056_bib31) 2008; 8 Kalogeras (10.1016/j.ijrobp.2016.11.056_bib16) 2008; 13 van der Steen-Banasik (10.1016/j.ijrobp.2016.11.056_bib24) 2009; 93 Huddart (10.1016/j.ijrobp.2016.11.056_bib33) 2012; 84 Eswara (10.1016/j.ijrobp.2016.11.056_bib32) 2012; 187 Gofrit (10.1016/j.ijrobp.2016.11.056_bib14) 2015; 33 Chamie (10.1016/j.ijrobp.2016.11.056_bib13) 2008; 102 Efstathiou (10.1016/j.ijrobp.2016.11.056_bib3) 2012; 61 Azuma (10.1016/j.ijrobp.2016.11.056_bib10) 2009; 32 Haresh (10.1016/j.ijrobp.2016.11.056_bib15) 2007; 3 Fedewa (10.1016/j.ijrobp.2016.11.056_bib30) 2009; 33 Munro (10.1016/j.ijrobp.2016.11.056_bib19) 2010; 77 AlGizawy (10.1016/j.ijrobp.2016.11.056_bib9) 2014; 13 Shelley (10.1016/j.ijrobp.2016.11.056_bib28) 2004; 16 Yadav (10.1016/j.ijrobp.2016.11.056_bib26) 2008; 24 Siegel (10.1016/j.ijrobp.2016.11.056_bib1) 2015; 65 Sun (10.1016/j.ijrobp.2016.11.056_bib38) 2015; 193 Bloom (10.1016/j.ijrobp.2016.11.056_bib11) 1982; 54 Arcangeli (10.1016/j.ijrobp.2016.11.056_bib29) 2015; 95 Trulson (10.1016/j.ijrobp.2016.11.056_bib23) 2014; 32 Mameghan (10.1016/j.ijrobp.2016.11.056_bib27) 1989; 63 Williamson (10.1016/j.ijrobp.2016.11.056_bib6) 2002; 21 Sell (10.1016/j.ijrobp.2016.11.056_bib21) 1991; 138 Sujenthiran (10.1016/j.ijrobp.2016.11.056_bib36) 2014; 13 Moher (10.1016/j.ijrobp.2016.11.056_bib4) 2009; 151 10.1016/j.ijrobp.2016.11.056_bib35 (10.1016/j.ijrobp.2016.11.056_bib2) 2005; 48 Miller (10.1016/j.ijrobp.2016.11.056_bib18) 1977; 39 10.1016/j.ijrobp.2016.11.056_bib8 Kotwal (10.1016/j.ijrobp.2016.11.056_bib17) 2008; 70 Supit (10.1016/j.ijrobp.2016.11.056_bib22) 2014; 37 Huddart (10.1016/j.ijrobp.2016.11.056_bib34) 2010; 106 Higgins (10.1016/j.ijrobp.2016.11.056_bib7) 2003; 327 Sun (10.1016/j.ijrobp.2016.11.056_bib37) 2014; 32 Parmar (10.1016/j.ijrobp.2016.11.056_bib5) 1998; 17 29280469 - Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):757. doi: 10.1016/j.ijrobp.2017.07.001. 29396699 - Strahlenther Onkol. 2018 Apr;194(4):358-359. doi: 10.1007/s00066-018-1274-6. 29280470 - Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):757-758. doi: 10.1016/j.ijrobp.2017.07.002. |
References_xml | – volume: 16 start-page: 166 year: 2004 end-page: 171 ident: bib28 article-title: A meta-analysis of randomised trials suggests a survival benefit for combined radiotherapy and radical cystectomy compared with radical radiotherapy for invasive bladder cancer: Are these data relevant to modern practice? publication-title: Clin Oncol (R Coll Radiol) – volume: 84 start-page: S119 year: 2012 end-page: S120 ident: bib33 article-title: Results of the SPARE feasibility study—selective bladder preservation against radical excision in muscle invasive T2/T3 transitional cell carcinoma of the bladder publication-title: Int J Radiat Oncol Biol Phys – volume: 37 start-page: 184 year: 2014 end-page: 189 ident: bib22 article-title: Outcomes of radical cystectomy and bladder preservation treatment for muscle-invasive urothelial carcinoma of the bladder publication-title: Asian J Surg – volume: 32 start-page: 592 year: 2009 end-page: 606 ident: bib10 article-title: Total cystectomy versus bladder preservation therapy for locally invasive bladder cancer: Effect of combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation publication-title: Am J Clin Oncol – volume: 8 start-page: 250 year: 2008 ident: bib31 article-title: Muscle invasive bladder cancer in Upper Egypt: The shift in risk factors and tumor characteristics publication-title: BMC Cancer – volume: 138 start-page: 193 year: 1991 end-page: 201 ident: bib21 article-title: Treatment of advanced bladder cancer category T2 T3 and T4a. A randomized multicenter study of preoperative irradiation and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor. DAVECA protocol 8201. Danish Vesical Cancer Group publication-title: Scand J Urol Nephrol Suppl – volume: 17 start-page: 2814 year: 1998 end-page: 2834 ident: bib5 article-title: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints publication-title: Stat Med – volume: 13 start-page: 428 year: 2014 end-page: 437 ident: bib9 article-title: Trimodality bladder-sparing approach versus radical cystectomy for invasive bladder cancer publication-title: J Radiother Practice – volume: 187 start-page: 463 year: 2012 end-page: 468 ident: bib32 article-title: Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer publication-title: J Urol – volume: 54 start-page: 136 year: 1982 end-page: 151 ident: bib11 article-title: Treatment of T3 bladder cancer: Controlled trial of pre-operative radiotherapy and radical cystectomy versus radical radiotherapy publication-title: Br J Urol – volume: 32 start-page: 334 year: 2014 ident: bib37 article-title: Comparative effectiveness of radical cystectomy versus bladder-sparing treatment for muscle-invasive urothelial carcinoma: A population-based report publication-title: J Clin Oncol – volume: 65 start-page: 5 year: 2015 end-page: 29 ident: bib1 article-title: Cancer statistics, 2015 publication-title: CA Cancer J Clin – volume: 39 start-page: 973 year: 1977 end-page: 980 ident: bib18 article-title: Bladder cancer: Superiority of preoperative irradiation and cystectomy in clinical stages B2 and C publication-title: Cancer – volume: 327 start-page: 557 year: 2003 end-page: 560 ident: bib7 article-title: Measuring inconsistency in meta-analyses publication-title: BMJ – volume: 63 start-page: 251 year: 1989 end-page: 258 ident: bib27 article-title: Invasive bladder cancer. Prognostic factors and results of radiotherapy with and without cystectomy publication-title: Br J Urol – volume: 102 start-page: 284 year: 2008 end-page: 290 ident: bib13 article-title: Cystectomy in the elderly: Does the survival benefit in younger patients translate to the octogenarians? publication-title: BJU Int – volume: 13 start-page: e123 year: 2014 ident: bib36 article-title: Long-term outcome following management of muscle invasive bladder cancer: Bladder-sparing Radical Therapy (BRT) and subsequent salvage cystectomy versus immediate primary cystectomy publication-title: Eur Urol – volume: 70 start-page: 456 year: 2008 end-page: 463 ident: bib17 article-title: Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center publication-title: Int J Radiat Oncol Biol Phys – volume: 21 start-page: 3337 year: 2002 end-page: 3351 ident: bib6 article-title: Aggregate data meta-analysis with time-to-event outcomes publication-title: Stat Med – volume: 193 start-page: e921 year: 2015 ident: bib38 article-title: MP72-01 Radical cystectomy versus bladder-sparing treatment for patients with muscle-invasive urothelial carcinoma of the urinary bladder: Q comparative effectiveness population-based study publication-title: J Urol – reference: Pokala N, Agarwal P, Kiran RP, et al. Comparative survival following different treatment modalities for stage T2-muscle invasive bladder cancer in octogenarians—a population based study. Presented at the Annual Meeting of the American Urological Association, May 14-19, 2011, Washington, DC. – reference: Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: – volume: 43 start-page: 246 year: 2003 end-page: 257 ident: bib12 article-title: A study of the morbidity, mortality and long-term survival following radical cystectomy and radical radiotherapy in the treatment of invasive bladder cancer in Yorkshire publication-title: Eur Urol – volume: 48 start-page: 202 year: 2005 end-page: 205 ident: bib2 article-title: Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data publication-title: Eur Urol – volume: 77 start-page: 119 year: 2010 end-page: 124 ident: bib19 article-title: A 10-year retrospective review of a nonrandomized cohort of 458 patients undergoing radical radiotherapy or cystectomy in Yorkshire, UK publication-title: Int J Radiat Oncol Biol Phys – volume: 106 start-page: 753 year: 2010 end-page: 755 ident: bib34 article-title: Life and death of SPARE (selective bladder preservation against radical excision): Reflections on why the SPARE trial closed publication-title: BJU Int – volume: 61 start-page: 705 year: 2012 end-page: 711 ident: bib3 article-title: Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: The MGH experience publication-title: Eur Urol – volume: 32 start-page: 425 year: 2014 end-page: 429 ident: bib23 article-title: Comparative survival following different treatment modalities for stage T2 bladder cancer in octogenarians publication-title: World J Urol – volume: 24 start-page: 48 year: 2008 end-page: 53 ident: bib26 article-title: Outcome following radical cystectomy and bladder-preservation therapy in patients with invasive carcinoma of urinary bladder publication-title: Indian J Urol – volume: 48 start-page: 239 year: 2005 end-page: 245 ident: bib20 article-title: Survival after bladder-preservation with brachytherapy versus radical cystectomy; a single institution experience publication-title: Eur Urol – volume: 33 start-page: 176 year: 2009 end-page: 181 ident: bib30 article-title: Incidence analyses of bladder cancer in the Nile delta region of Egypt publication-title: Cancer Epidemiol – volume: 93 start-page: 352 year: 2009 end-page: 357 ident: bib24 article-title: Brachytherapy versus cystectomy in solitary bladder cancer: A case control, multicentre, East-Netherlands study publication-title: Radiother Oncol – volume: 33 start-page: 19.e1 year: 2015 end-page: 19.e5 ident: bib14 article-title: Radical cystectomy vs. chemoradiation in T2-4aN0M0 bladder cancer: A case-control study publication-title: Urol Oncol – volume: 3 start-page: 81 year: 2007 end-page: 85 ident: bib15 article-title: A prospective study evaluating surgery and chemo radiation in muscle invasive bladder cancer publication-title: J Cancer Res Ther – volume: 13 start-page: 353 year: 2008 end-page: 358 ident: bib16 article-title: Radical therapy for muscle-infiltrating bladder cancer (cystectomy or radiotherapy): Does age affect the final therapeutic benefit for the patient? publication-title: J BUON – volume: 48 start-page: 587 year: 1976 end-page: 594 ident: bib25 article-title: The management of deeply infiltrating (T3) bladder carcinoma: Controlled trial of radical radiotherapy versus preoperative radiotherapy and radical cystectomy (first report) publication-title: Br J Urol – volume: 151 start-page: 264 year: 2009 end-page: 269 ident: bib4 article-title: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement publication-title: Ann Intern Med – reference: . Accessed November 17, 2016. – volume: 95 start-page: 387 year: 2015 end-page: 396 ident: bib29 article-title: Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials publication-title: Crit Rev Oncol Hematol – volume: 187 start-page: 463 year: 2012 ident: 10.1016/j.ijrobp.2016.11.056_bib32 article-title: Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer publication-title: J Urol doi: 10.1016/j.juro.2011.09.159 – volume: 65 start-page: 5 year: 2015 ident: 10.1016/j.ijrobp.2016.11.056_bib1 article-title: Cancer statistics, 2015 publication-title: CA Cancer J Clin doi: 10.3322/caac.21254 – volume: 93 start-page: 352 year: 2009 ident: 10.1016/j.ijrobp.2016.11.056_bib24 article-title: Brachytherapy versus cystectomy in solitary bladder cancer: A case control, multicentre, East-Netherlands study publication-title: Radiother Oncol doi: 10.1016/j.radonc.2009.04.020 – volume: 106 start-page: 753 year: 2010 ident: 10.1016/j.ijrobp.2016.11.056_bib34 article-title: Life and death of SPARE (selective bladder preservation against radical excision): Reflections on why the SPARE trial closed publication-title: BJU Int doi: 10.1111/j.1464-410X.2010.09537.x – volume: 3 start-page: 81 year: 2007 ident: 10.1016/j.ijrobp.2016.11.056_bib15 article-title: A prospective study evaluating surgery and chemo radiation in muscle invasive bladder cancer publication-title: J Cancer Res Ther doi: 10.4103/0973-1482.34684 – volume: 21 start-page: 3337 year: 2002 ident: 10.1016/j.ijrobp.2016.11.056_bib6 article-title: Aggregate data meta-analysis with time-to-event outcomes publication-title: Stat Med doi: 10.1002/sim.1303 – volume: 13 start-page: 428 year: 2014 ident: 10.1016/j.ijrobp.2016.11.056_bib9 article-title: Trimodality bladder-sparing approach versus radical cystectomy for invasive bladder cancer publication-title: J Radiother Practice doi: 10.1017/S1460396914000107 – volume: 32 start-page: 425 year: 2014 ident: 10.1016/j.ijrobp.2016.11.056_bib23 article-title: Comparative survival following different treatment modalities for stage T2 bladder cancer in octogenarians publication-title: World J Urol doi: 10.1007/s00345-013-1123-2 – volume: 33 start-page: 176 year: 2009 ident: 10.1016/j.ijrobp.2016.11.056_bib30 article-title: Incidence analyses of bladder cancer in the Nile delta region of Egypt publication-title: Cancer Epidemiol doi: 10.1016/j.canep.2009.08.008 – volume: 32 start-page: 334 year: 2014 ident: 10.1016/j.ijrobp.2016.11.056_bib37 article-title: Comparative effectiveness of radical cystectomy versus bladder-sparing treatment for muscle-invasive urothelial carcinoma: A population-based report publication-title: J Clin Oncol doi: 10.1200/jco.2014.32.4_suppl.334 – volume: 327 start-page: 557 year: 2003 ident: 10.1016/j.ijrobp.2016.11.056_bib7 article-title: Measuring inconsistency in meta-analyses publication-title: BMJ doi: 10.1136/bmj.327.7414.557 – volume: 48 start-page: 239 year: 2005 ident: 10.1016/j.ijrobp.2016.11.056_bib20 article-title: Survival after bladder-preservation with brachytherapy versus radical cystectomy; a single institution experience publication-title: Eur Urol doi: 10.1016/j.eururo.2005.03.022 – volume: 17 start-page: 2814 year: 1998 ident: 10.1016/j.ijrobp.2016.11.056_bib5 article-title: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints publication-title: Stat Med doi: 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8 – volume: 95 start-page: 387 year: 2015 ident: 10.1016/j.ijrobp.2016.11.056_bib29 article-title: Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials publication-title: Crit Rev Oncol Hematol doi: 10.1016/j.critrevonc.2015.04.006 – volume: 16 start-page: 166 year: 2004 ident: 10.1016/j.ijrobp.2016.11.056_bib28 article-title: A meta-analysis of randomised trials suggests a survival benefit for combined radiotherapy and radical cystectomy compared with radical radiotherapy for invasive bladder cancer: Are these data relevant to modern practice? publication-title: Clin Oncol (R Coll Radiol) doi: 10.1016/j.clon.2003.10.001 – volume: 77 start-page: 119 year: 2010 ident: 10.1016/j.ijrobp.2016.11.056_bib19 article-title: A 10-year retrospective review of a nonrandomized cohort of 458 patients undergoing radical radiotherapy or cystectomy in Yorkshire, UK publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2009.04.050 – volume: 138 start-page: 193 year: 1991 ident: 10.1016/j.ijrobp.2016.11.056_bib21 publication-title: Scand J Urol Nephrol Suppl doi: 10.1080/21681805.1991.12068888 – ident: 10.1016/j.ijrobp.2016.11.056_bib35 doi: 10.1016/j.juro.2011.02.1879 – volume: 43 start-page: 246 year: 2003 ident: 10.1016/j.ijrobp.2016.11.056_bib12 article-title: A study of the morbidity, mortality and long-term survival following radical cystectomy and radical radiotherapy in the treatment of invasive bladder cancer in Yorkshire publication-title: Eur Urol doi: 10.1016/S0302-2838(02)00581-X – volume: 48 start-page: 587 year: 1976 ident: 10.1016/j.ijrobp.2016.11.056_bib25 article-title: The management of deeply infiltrating (T3) bladder carcinoma: Controlled trial of radical radiotherapy versus preoperative radiotherapy and radical cystectomy (first report) publication-title: Br J Urol doi: 10.1111/j.1464-410X.1976.tb06705.x – volume: 13 start-page: 353 year: 2008 ident: 10.1016/j.ijrobp.2016.11.056_bib16 article-title: Radical therapy for muscle-infiltrating bladder cancer (cystectomy or radiotherapy): Does age affect the final therapeutic benefit for the patient? publication-title: J BUON – volume: 61 start-page: 705 year: 2012 ident: 10.1016/j.ijrobp.2016.11.056_bib3 article-title: Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: The MGH experience publication-title: Eur Urol doi: 10.1016/j.eururo.2011.11.010 – volume: 193 start-page: e921 year: 2015 ident: 10.1016/j.ijrobp.2016.11.056_bib38 article-title: MP72-01 Radical cystectomy versus bladder-sparing treatment for patients with muscle-invasive urothelial carcinoma of the urinary bladder: Q comparative effectiveness population-based study publication-title: J Urol doi: 10.1016/j.juro.2015.02.2635 – volume: 63 start-page: 251 year: 1989 ident: 10.1016/j.ijrobp.2016.11.056_bib27 article-title: Invasive bladder cancer. Prognostic factors and results of radiotherapy with and without cystectomy publication-title: Br J Urol doi: 10.1111/j.1464-410X.1989.tb05185.x – volume: 84 start-page: S119 year: 2012 ident: 10.1016/j.ijrobp.2016.11.056_bib33 article-title: Results of the SPARE feasibility study—selective bladder preservation against radical excision in muscle invasive T2/T3 transitional cell carcinoma of the bladder publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2012.07.211 – ident: 10.1016/j.ijrobp.2016.11.056_bib8 – volume: 39 start-page: 973 year: 1977 ident: 10.1016/j.ijrobp.2016.11.056_bib18 article-title: Bladder cancer: Superiority of preoperative irradiation and cystectomy in clinical stages B2 and C publication-title: Cancer doi: 10.1002/1097-0142(197702)39:2+<973::AID-CNCR2820390737>3.0.CO;2-O – volume: 13 start-page: e123 year: 2014 ident: 10.1016/j.ijrobp.2016.11.056_bib36 article-title: Long-term outcome following management of muscle invasive bladder cancer: Bladder-sparing Radical Therapy (BRT) and subsequent salvage cystectomy versus immediate primary cystectomy publication-title: Eur Urol doi: 10.1016/S1569-9056(14)60124-X – volume: 48 start-page: 202 year: 2005 ident: 10.1016/j.ijrobp.2016.11.056_bib2 article-title: Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data publication-title: Eur Urol doi: 10.1016/j.eururo.2005.04.006 – volume: 102 start-page: 284 year: 2008 ident: 10.1016/j.ijrobp.2016.11.056_bib13 article-title: Cystectomy in the elderly: Does the survival benefit in younger patients translate to the octogenarians? publication-title: BJU Int doi: 10.1111/j.1464-410X.2008.07636.x – volume: 37 start-page: 184 year: 2014 ident: 10.1016/j.ijrobp.2016.11.056_bib22 article-title: Outcomes of radical cystectomy and bladder preservation treatment for muscle-invasive urothelial carcinoma of the bladder publication-title: Asian J Surg doi: 10.1016/j.asjsur.2014.01.010 – volume: 32 start-page: 592 year: 2009 ident: 10.1016/j.ijrobp.2016.11.056_bib10 article-title: Total cystectomy versus bladder preservation therapy for locally invasive bladder cancer: Effect of combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation publication-title: Am J Clin Oncol doi: 10.1097/COC.0b013e318199fb42 – volume: 151 start-page: 264 year: 2009 ident: 10.1016/j.ijrobp.2016.11.056_bib4 article-title: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement publication-title: Ann Intern Med doi: 10.7326/0003-4819-151-4-200908180-00135 – volume: 24 start-page: 48 year: 2008 ident: 10.1016/j.ijrobp.2016.11.056_bib26 article-title: Outcome following radical cystectomy and bladder-preservation therapy in patients with invasive carcinoma of urinary bladder publication-title: Indian J Urol doi: 10.4103/0970-1591.38603 – volume: 70 start-page: 456 year: 2008 ident: 10.1016/j.ijrobp.2016.11.056_bib17 article-title: Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2007.06.030 – volume: 8 start-page: 250 year: 2008 ident: 10.1016/j.ijrobp.2016.11.056_bib31 article-title: Muscle invasive bladder cancer in Upper Egypt: The shift in risk factors and tumor characteristics publication-title: BMC Cancer doi: 10.1186/1471-2407-8-250 – volume: 54 start-page: 136 year: 1982 ident: 10.1016/j.ijrobp.2016.11.056_bib11 article-title: Treatment of T3 bladder cancer: Controlled trial of pre-operative radiotherapy and radical cystectomy versus radical radiotherapy publication-title: Br J Urol doi: 10.1111/j.1464-410X.1982.tb13537.x – volume: 33 start-page: 19.e1 year: 2015 ident: 10.1016/j.ijrobp.2016.11.056_bib14 article-title: Radical cystectomy vs. chemoradiation in T2-4aN0M0 bladder cancer: A case-control study publication-title: Urol Oncol doi: 10.1016/j.urolonc.2014.09.014 – reference: 29280469 - Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):757. doi: 10.1016/j.ijrobp.2017.07.001. – reference: 29396699 - Strahlenther Onkol. 2018 Apr;194(4):358-359. doi: 10.1007/s00066-018-1274-6. – reference: 29280470 - Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):757-758. doi: 10.1016/j.ijrobp.2017.07.002. |
SSID | ssj0001174 |
Score | 2.504069 |
SecondaryResourceType | review_article |
Snippet | To perform a comprehensive comparison of overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), and treatment-related... Purpose To perform a comprehensive comparison of overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), and treatment-related... To perform a comprehensive comparison of overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), and treatment-related... Purpose: To perform a comprehensive comparison of overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), and... |
SourceID | osti proquest pubmed crossref elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1002 |
SubjectTerms | Aged Aged, 80 and over BLADDER Chemoradiotherapy - mortality Chemoradiotherapy - statistics & numerical data CHEMOTHERAPY Combined Modality Therapy Cystectomy - mortality Cystectomy - statistics & numerical data Disease-Free Survival Female Hematology, Oncology and Palliative Medicine Humans Male Middle Aged Neoplasm Invasiveness NEOPLASMS Postoperative Complications - mortality Postoperative Complications - prevention & control Prevalence Radiation Injuries - mortality Radiation Injuries - prevention & control RADICALS Radiology RADIOLOGY AND NUCLEAR MEDICINE RADIOTHERAPY Risk Factors Survival Rate Treatment Outcome Urinary Bladder Neoplasms - mortality Urinary Bladder Neoplasms - therapy |
Title | Radical Cystectomy Compared to Combined Modality Treatment for Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0360301616335490 https://www.clinicalkey.es/playcontent/1-s2.0-S0360301616335490 https://dx.doi.org/10.1016/j.ijrobp.2016.11.056 https://www.ncbi.nlm.nih.gov/pubmed/28332983 https://www.proquest.com/docview/1880469693 https://www.osti.gov/biblio/22649890 |
Volume | 97 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9NAEF2FVEJcEN8NFLRI3CpH9nrt2NxCBApU4dCGNrfVer2WGpUYJQ6HnPmn_BFmsru20w-19GJZkdd2PM87b8ZvZgn5wPxcJn4qIcjJE49nnHvo570i8HMVsEzmIdY7T77H4x_82yyadTp_W6qldZX11ebaupL7WBV-A7tilex_WLY-KfwA-2Bf2IKFYXsnGx9L85VlhO2YVVX-tO83asqBU8I-xL2wPylzQ7entawc1YWT9QpO6H1d_JZbEfunC5yGlocjRMLS1KyfNJ2ebQ_-rTJDV9Jz_Uza_HY3wdhqS7HEHgiGnS5UXSGTNcUyJsVSM_xTXORpVZnPUae4RHQtBTmzKe4x0FpMdzdJ9c2mtAnaRqaJYqNzszK8LRE4HPbbuQ7wn41EZpuAc0U4OxpR8MHgSvzAdtQ283gySD2gUrP2RG-EwBbQUWvWxja0LQYAnMu_1ruYRMe8fz5flhk2Ow3iPraAjS41897SgxO8L7wtYLwhROH-A7LHIJaByXhveHR8dlQThsA2C3f_w1V4bmWIV691E4PqluAUbg6UtoRp-oQ8tpEOHRrYPiUdvXhGHk6sluM5-WPRSxv0UodeWpXUoZc69NIavRTQSy-hl1r0UoPej3RIG-xSg10K2KU72H1Bpl8-T0djz64J4qko5pWXxpFkRZzDNKCiSGtg45pHPMgUBy5d-DpWMk90wUKpc6C3mR-GRQ7H-MpnWRS-JN0FQHGfUKZipgZFxuI042leJGnEtRrwRLKMyWDQI6F7zELZfvm4bMuFcMLIuTDGEWgcCKUFGKdHvHrUL9Mv5pbjI2dB4WqhwXsLgNwt4wbXjdMr-2avRCBWTPjiCgzbIy3LNuz5Dtc8QIjhKGwwrVCJB8OwFD9N8MTvHfQE-Cj88CgXulzDrQBJ4HEap2GPvDKYrB8OhDchS5Pw9b1v6w151MwVB6RbLdf6LUQKVfbOvmn_AE8rGAU |
linkProvider | Library Specific Holdings |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Radical+Cystectomy+Compared+to+Combined+Modality+Treatment+for+Muscle-Invasive+Bladder+Cancer%3A+A+Systematic+Review+and+Meta-Analysis&rft.jtitle=International+journal+of+radiation+oncology%2C+biology%2C+physics&rft.au=Vashistha%2C+Vishal&rft.au=Wang%2C+Hanzhang&rft.au=Mazzone%2C+Andrew&rft.au=Liss%2C+Michael+A.&rft.date=2017-04-01&rft.pub=Elsevier+Inc&rft.issn=0360-3016&rft.eissn=1879-355X&rft.volume=97&rft.issue=5&rft.spage=1002&rft.epage=1020&rft_id=info:doi/10.1016%2Fj.ijrobp.2016.11.056&rft.externalDocID=S0360301616335490 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F03603016%2FS0360301616X00211%2Fcov150h.gif |